JP6253986B2 - コレクション及びその使用方法 - Google Patents

コレクション及びその使用方法 Download PDF

Info

Publication number
JP6253986B2
JP6253986B2 JP2013539286A JP2013539286A JP6253986B2 JP 6253986 B2 JP6253986 B2 JP 6253986B2 JP 2013539286 A JP2013539286 A JP 2013539286A JP 2013539286 A JP2013539286 A JP 2013539286A JP 6253986 B2 JP6253986 B2 JP 6253986B2
Authority
JP
Japan
Prior art keywords
seq
antibody
collection
germline
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013539286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500725A5 (enExample
JP2014500725A (ja
Inventor
ウルリンガー，シュテファーニエ
ティラー，トーマス
シュスター，イングリット
シュタルク，イボンヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of JP2014500725A publication Critical patent/JP2014500725A/ja
Publication of JP2014500725A5 publication Critical patent/JP2014500725A5/ja
Application granted granted Critical
Publication of JP6253986B2 publication Critical patent/JP6253986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013539286A 2010-11-19 2011-11-18 コレクション及びその使用方法 Active JP6253986B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41536710P 2010-11-19 2010-11-19
EP10191910 2010-11-19
EP10191910.8 2010-11-19
US61/415,367 2010-11-19
US201161494452P 2011-06-08 2011-06-08
US61/494,452 2011-06-08
PCT/EP2011/070473 WO2012066129A1 (en) 2010-11-19 2011-11-18 A collection and methods for its use

Publications (3)

Publication Number Publication Date
JP2014500725A JP2014500725A (ja) 2014-01-16
JP2014500725A5 JP2014500725A5 (enExample) 2015-01-15
JP6253986B2 true JP6253986B2 (ja) 2017-12-27

Family

ID=44041472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539286A Active JP6253986B2 (ja) 2010-11-19 2011-11-18 コレクション及びその使用方法

Country Status (18)

Country Link
US (3) US8367586B2 (enExample)
EP (1) EP2640742B1 (enExample)
JP (1) JP6253986B2 (enExample)
KR (1) KR101938021B1 (enExample)
CN (1) CN103237809B (enExample)
AU (1) AU2011331129B2 (enExample)
CA (1) CA2816558C (enExample)
DK (1) DK2640742T3 (enExample)
ES (1) ES2696548T3 (enExample)
HR (1) HRP20181811T1 (enExample)
IL (1) IL226364B (enExample)
MX (1) MX353795B (enExample)
NZ (1) NZ609707A (enExample)
PL (1) PL2640742T3 (enExample)
RU (1) RU2603080C2 (enExample)
SG (2) SG10201509257VA (enExample)
WO (1) WO2012066129A1 (enExample)
ZA (1) ZA201303566B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102993305B (zh) 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
MY191512A (en) * 2013-09-18 2022-06-28 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
WO2015089080A2 (en) 2013-12-09 2015-06-18 Adimab, Llc Polyclonal mixtures of antibodies, and methods of making and using them
US10654933B2 (en) * 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
CA3014842A1 (en) 2016-02-19 2017-08-24 Morphosys Ag Antibodies for il-17c
EP3443087B1 (en) * 2016-04-12 2024-09-18 Medimmune, LLC Immune repertoire mining
US11254734B2 (en) 2016-11-14 2022-02-22 Morphosys Ag Fab molecules with a rodent hinge region and a non-rodent CH1 region
WO2019099454A2 (en) 2017-11-15 2019-05-23 Philippe Valadon Highly functional antibody libraries
EP3793596A1 (en) 2018-05-16 2021-03-24 MorphoSys AG Antibodies targeting glycoprotein vi
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
CA3182339A1 (en) 2020-05-20 2021-11-25 Institut Curie Synthetic single domain library
US20230305021A1 (en) 2020-06-08 2023-09-28 Immundiagnostik Ag Improved method and test system for in-vitro determination of drug antibodies in blood
JP7851303B2 (ja) 2020-09-24 2026-04-24 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒトｃｄ３イプシロンに結合する新規なヒト抗体
JP2025513714A (ja) 2022-03-22 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃｄ３に特異的な脱免疫抗体
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
WO1992015678A1 (en) 1991-03-01 1992-09-17 Stratagene Pcr generated dicistronic dna molecules for producing antibodies
ATE175997T1 (de) 1991-08-10 1999-02-15 Medical Res Council Behandlung von zellpopulationen
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
EP0725838A4 (en) 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
US20010049107A1 (en) 1994-01-31 2001-12-06 Boston University Polyclonal antibody libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PT1157041E (pt) 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
JP4860098B2 (ja) 2000-12-18 2012-01-25 ダイアックス、コープ 遺伝的パッケージの焦点を合わせたライブラリー
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2004013276A2 (en) 2002-07-30 2004-02-12 Morphosys Ip Gmbh Novel tricistronic vectors and uses therefor
US8557743B2 (en) 2002-09-05 2013-10-15 Dyax Corp. Display library process
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
WO2005023993A2 (en) 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP2343321A1 (en) 2003-11-12 2011-07-13 Patrys Limited Human antibodies specific for carcinoma
EP1718765A2 (en) 2004-01-26 2006-11-08 Isis Innovation Limited Molecular analysis
ATE505727T1 (de) 2004-05-26 2011-04-15 Fraunhofer Ges Forschung Isolation allergen-spezifischer immunoglobulin- gene aus humanen b-zellen von atopikern
EP1781680B8 (en) 2004-07-06 2016-05-18 Bioren, LLC Universal antibody libraries
WO2006028987A2 (en) 2004-09-02 2006-03-16 Bioarray Solutions Ltd. Nucleic acid amplification with integrated multiplex detection
US20060078898A1 (en) 2004-10-12 2006-04-13 Curry Bo U Methods and compositions for reducing label variation in array-based comparative genome hybridization assays II
AU2006210660B2 (en) 2005-02-01 2011-12-01 Morphosys Ag Libraries and methods for isolating antibodies
RU2311927C2 (ru) * 2005-08-15 2007-12-10 Федеральное государственное унитарное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" КОМБИНАТОРНАЯ ФАГМИДНАЯ БИБЛИОТЕКА ОДНОЦЕПОЧЕЧНЫХ АНТИТЕЛ ЧЕЛОВЕКА, ОБОГАЩЕННАЯ АНТИТЕЛАМИ ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ФАГМИДНАЯ ДНК pHEN-2A8, СОДЕРЖАЩАЯ УНИКАЛЬНЫЙ ГЕН ОДНОЦЕПОЧЕЧНОГО АНТИТЕЛА ЧЕЛОВЕКА, СПОСОБНОГО НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ, И ИСКУССТВЕННОЕ ОДНОЦЕПОЧЕЧНОЕ АНТИТЕЛО ЧЕЛОВЕКА 2A8, СПОСОБНОЕ НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
JP5405831B2 (ja) 2005-12-20 2014-02-05 モルフォシス アーゲー Ｈ−ｃｄｒ３領域の新規集合体およびその使用
AU2007248559A1 (en) 2006-05-04 2007-11-15 Abmaxis Inc. Cross-species and multi-species display systems
EP1918302A3 (en) * 2006-05-18 2009-11-18 AvantGen, Inc. Methods for the identification and the isolation of epitope specific antibodies
MX2010000232A (es) 2007-08-21 2010-06-02 Morphosys Ag Metodos mejorados para la formacion de enlaces disulfuro.
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP2088432A1 (en) 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
EP2100970B1 (en) 2008-03-13 2017-05-10 National Institute of Immunology Ig genes specific oligonucleotides and uses thereof
WO2010028791A1 (en) 2008-09-10 2010-03-18 Philochem Ag Display library for antibody selection
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
WO2010130824A2 (en) * 2009-05-15 2010-11-18 Morphosys Ag Collections and uses thereof
NZ596603A (en) * 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
DK2528944T3 (en) 2010-01-29 2015-09-14 Morphosys Ag Rodent combinatorial antibody libraries

Also Published As

Publication number Publication date
NZ609707A (en) 2014-12-24
SG10201509257VA (en) 2015-12-30
CN103237809B (zh) 2016-09-07
MX353795B (es) 2018-01-30
RU2013126025A (ru) 2014-12-27
IL226364A0 (en) 2013-07-31
CA2816558A1 (en) 2012-05-24
US20130236902A1 (en) 2013-09-12
AU2011331129B2 (en) 2016-10-06
ES2696548T3 (es) 2019-01-16
ZA201303566B (en) 2014-07-30
EP2640742B1 (en) 2018-08-15
HRP20181811T1 (hr) 2018-12-28
US8728981B2 (en) 2014-05-20
MX2013005614A (es) 2013-11-21
SG189950A1 (en) 2013-06-28
CA2816558C (en) 2020-12-29
AU2011331129A1 (en) 2013-05-23
DK2640742T3 (en) 2018-12-03
PL2640742T3 (pl) 2019-01-31
CN103237809A (zh) 2013-08-07
IL226364B (en) 2020-11-30
US8367586B2 (en) 2013-02-05
US20120129717A1 (en) 2012-05-24
US9541559B2 (en) 2017-01-10
EP2640742A1 (en) 2013-09-25
WO2012066129A1 (en) 2012-05-24
US20140206575A1 (en) 2014-07-24
KR101938021B1 (ko) 2019-01-11
KR20140015274A (ko) 2014-02-06
JP2014500725A (ja) 2014-01-16
RU2603080C2 (ru) 2016-11-20

Similar Documents

Publication Publication Date Title
US8367586B2 (en) Collection and methods for its use
US10647757B2 (en) Collection and methods for its use
KR20200020819A (ko) 개과 항체 라이브러리
HK1187626B (en) A collection and methods for its use
HK1187626A (en) A collection and methods for its use
GB2616707A (en) Methods
HK1168635B (en) A collection and methods for its use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171129

R150 Certificate of patent or registration of utility model

Ref document number: 6253986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250